Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response
Zhang P., Kitchen-Smith I., Xiong L., Stracquadanio G., Brown K., Richter P., Wallace M., Bond E., Sahgal N., Moore S., Nornes S., De Val S., Surakhy M., Sims D., Wang X., Bell DA., Zeron-Medina J., Jiang Y., Ryan A., Selfe J., Shipley J., Kar S., Pharoah P., Loveday C., Jansen R., Grochola LF., Palles C., Protheroe A., Millar V., Ebner D., Pagadala M., Blagden SP., Maughan T., Domingo E., Tomlinson I., Turnbull C., Carter H., Bond G.
AbstractInsights into oncogenesis derived from cancer susceptibility loci could facilitate better cancer management and treatment through precision oncology. However, therapeutic applications have thus far been limited by our current lack of understanding regarding both their interactions with somatic cancer driver mutations and their influence on tumorigenesis. Here, by integrating germline datasets relating to cancer susceptibility with tumour data capturing somatically-acquired genetic variation, we provide evidence that single nucleotide polymorphism (SNPs) and somatic mutations in the p53 tumor suppressor pathway can interact to influence cancer development, progression and treatment response. We go on to provide human genetic evidence of a tumor-promoting role for the pro-survival activities of p53, which supports the development of more effective therapy combinations through their inhibition in cancers retaining wild-type p53.SignificanceWe describe significant interactions between heritable and somatic genetic variants in the p53 pathway that affect cancer susceptibility, progression and treatment response. Our results offer evidence of how cancer susceptibility SNPs can interact with cancer driver genes to affect cancer progression and identify novel therapeutic targets.